Two 340B Terminations, Two Paybacks to Manufacturers in Latest Provider Audit Findings

HRSA provider audits
Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.
Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

2024 Congressional 340B Outlook: Overhaul Unlikely Without Major Legal Developments, Senate Deal

US Capitol
A Senate Committee recently approved the FY25 Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act.
In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package, lobbyists [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles

In 2023, Arkansas became the first state to move to enforce a 340B contract pharmacy law as manufacturer restrictions continued to increase.
In 2023, the battle over the use of contract pharmacy arrangements by 340B providers was marked by increasing drugmaker restrictions, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Hospitals Are Not the Only 340B Providers Under Scrutiny

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
Veteran 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

Lilly
Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions

Takeda 340B
Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

HRSA Unveils Web Page with Patient Definition Compliance Resources, Guidance

HRSA patient definition web page
HRSA released a new web page with resources on the agency's 340B program patient definition and compliance guidelines.
In the wake of a high-profile federal court ruling casting doubt on the definition of eligible “patient” in the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Michigan to Increase Medicaid Payment for 340B Hospitals, Adds Reporting Requirements

The Michigan Department of Health and Human Services released a new 340B hospital billing and reporting rule.
At the start of 2024, Michigan 340B hospitals can bill the state at higher payment rates for outpatient drugs; later [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.
Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live